Switching from TNFα inhibitor to tacrolimus as maintenance therapy in rheumatoid arthritis after achieving low disease activity with TNFα inhibitors and methotrexate: 24-week result from a non-randomized, prospective, active-controlled trial.
Sang Youn JungJung Hee KohKi-Jo KimYong-Wook ParkHyung-In YangSung Jae ChoiJisoo LeeChan-Bum ChoiWan-Uk KimPublished in: Arthritis research & therapy (2021)
Korea CDC CRIS, KCT0005868 . Registered 4 February 2021-retrospectively registered.
Keyphrases
- rheumatoid arthritis
- disease activity
- double blind
- placebo controlled
- open label
- rheumatoid arthritis patients
- ankylosing spondylitis
- juvenile idiopathic arthritis
- interstitial lung disease
- phase iii
- clinical trial
- systemic lupus erythematosus
- phase ii
- study protocol
- high dose
- stem cells
- randomized controlled trial
- mesenchymal stem cells
- smoking cessation